# ONI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oni

- Industry: Healthcare IT
- Headquarters: Oxford, UK
- Total disclosed funding: $75M
- Latest round: Series B (Jan 20, 2022)
- Investors on record: 6

## About

Based in Oxford, UK, and founded in 2016, ONI, a.k.a. ONI Bio, is a biotech company specializing in super-resolution microscopy, which allows researchers to zoom in on molecules and structures within living cells. As of 2023, the company is led by Paul Scagnetti (CEO). In January 2022, ONI raised USD 75 million in Series B funding from investors ARCH Venture Partners and Casdin Capital, with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, and Axon Ventures. 

The company offers a cloud-based software platform called CODI (Collaborative Discovery) that provides researchers with the possibility of sharing datasets with different degrees of privacy, enabling others to not only visualize datasets but also how they have been processed to reach scientific conclusions. ONI Bio also offers an EV Profiling App on CODI that can quantify size and biomarker distributions from a collection of single extracellular vesicles (EVs), with a range of tools from drift correction, single-molecule filtering, clustering, cluster filtering, and counting of biomarker distribution. ONI Bio has published over 200 papers with their products.

## Funding rounds

- Series B, Jan 20, 2022, $75M — ARCH Venture Partners, ARTIS Ventures, Casdin Capital, Vertical Venture Partners, Section 32, Axon Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- ARTIS Ventures (https://capitalatlas.ai/funds/artis-ventures) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Vertical Venture Partners (https://capitalatlas.ai/funds/vertical-venture-partners) — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Axon Ventures — Series B